'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma

Leuk Lymphoma. 2018 Jun;59(6):1514-1516. doi: 10.1080/10428194.2017.1387911. Epub 2017 Oct 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Australia
  • Drug Resistance, Neoplasm
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology*
  • Recurrence
  • Retreatment
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Thalidomide
  • pomalidomide